IXICO
@ixico.bsky.social
A global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
The progress towards a scalable blood‑based test for Alzheimer’s disease represents a pivotal moment in early detection.
IXICO supports this progress as imaging partner for the Bio‑Hermes‑002 study with @GAP_Foundation, @lifearc1 and @UKDRI
www.bbc.co.uk/news/article...
IXICO supports this progress as imaging partner for the Bio‑Hermes‑002 study with @GAP_Foundation, @lifearc1 and @UKDRI
www.bbc.co.uk/news/article...
January 20, 2026 at 9:46 AM
The progress towards a scalable blood‑based test for Alzheimer’s disease represents a pivotal moment in early detection.
IXICO supports this progress as imaging partner for the Bio‑Hermes‑002 study with @GAP_Foundation, @lifearc1 and @UKDRI
www.bbc.co.uk/news/article...
IXICO supports this progress as imaging partner for the Bio‑Hermes‑002 study with @GAP_Foundation, @lifearc1 and @UKDRI
www.bbc.co.uk/news/article...
Blog: Advancing Amyloid Assessment in PET Imaging: Integrating AI with Quantitative Metrics
📥 Missed us at HAI 2025? Here’s a summary of our poster in this blog: ixico.com/news-and-res...
📥 Missed us at HAI 2025? Here’s a summary of our poster in this blog: ixico.com/news-and-res...
January 14, 2026 at 11:55 AM
Blog: Advancing Amyloid Assessment in PET Imaging: Integrating AI with Quantitative Metrics
📥 Missed us at HAI 2025? Here’s a summary of our poster in this blog: ixico.com/news-and-res...
📥 Missed us at HAI 2025? Here’s a summary of our poster in this blog: ixico.com/news-and-res...
Thank you to everyone who visited us at our poster at HAI 2026!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 71)
If you’re around at HAI 2026, let’s meet! www.ixico.com/contact-us
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 71)
If you’re around at HAI 2026, let’s meet! www.ixico.com/contact-us
January 13, 2026 at 6:25 PM
Thank you to everyone who visited us at our poster at HAI 2026!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 71)
If you’re around at HAI 2026, let’s meet! www.ixico.com/contact-us
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 71)
If you’re around at HAI 2026, let’s meet! www.ixico.com/contact-us
We're here at HAI 2025!
Robin Wolz and Jane Waugh will be around to present and talk with the community!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET #71
Let's meet - www.ixico.com/contact-us
Robin Wolz and Jane Waugh will be around to present and talk with the community!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET #71
Let's meet - www.ixico.com/contact-us
January 13, 2026 at 9:56 AM
We're here at HAI 2025!
Robin Wolz and Jane Waugh will be around to present and talk with the community!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET #71
Let's meet - www.ixico.com/contact-us
Robin Wolz and Jane Waugh will be around to present and talk with the community!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET #71
Let's meet - www.ixico.com/contact-us
Next week, we’ll be at HAI 2026 in San Juan!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 208)
Let’s connect: www.ixico.com/contact-us
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 208)
Let’s connect: www.ixico.com/contact-us
January 8, 2026 at 11:37 AM
Next week, we’ll be at HAI 2026 in San Juan!
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 208)
Let’s connect: www.ixico.com/contact-us
📌 Poster: ID Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET (ID: 208)
Let’s connect: www.ixico.com/contact-us
We'll be at HAI 2026 in San Juan, Puerto Rico!
Robin Wolz and Jane Waugh will be there to discuss advances in Alzheimer’s imaging.
📌 Poster: Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET
Robin Wolz and Jane Waugh will be there to discuss advances in Alzheimer’s imaging.
📌 Poster: Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET
December 17, 2025 at 2:51 PM
We'll be at HAI 2026 in San Juan, Puerto Rico!
Robin Wolz and Jane Waugh will be there to discuss advances in Alzheimer’s imaging.
📌 Poster: Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET
Robin Wolz and Jane Waugh will be there to discuss advances in Alzheimer’s imaging.
📌 Poster: Agreement Between Amyloid Status Prediction from Visual Read, SUVR Thresholding, and AI-Based Interpretation of Amyloid PET
Imaging is key in Parkinson’s clinical research—but getting it right matters.
From modality selection to operational best practices, our quick guide covers the essentials for successful imaging in trials.
Read more: ixico.com/news-and-res...
From modality selection to operational best practices, our quick guide covers the essentials for successful imaging in trials.
Read more: ixico.com/news-and-res...
December 10, 2025 at 11:42 AM
Imaging is key in Parkinson’s clinical research—but getting it right matters.
From modality selection to operational best practices, our quick guide covers the essentials for successful imaging in trials.
Read more: ixico.com/news-and-res...
From modality selection to operational best practices, our quick guide covers the essentials for successful imaging in trials.
Read more: ixico.com/news-and-res...
Today IXICO announced its 2025 financial results demonstrating how the disciplined execution of its “Innovate Lead Scale" strategy has delivered 13% revenue growth with commercial traction further accelerating into FY26.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
December 9, 2025 at 7:12 AM
Today IXICO announced its 2025 financial results demonstrating how the disciplined execution of its “Innovate Lead Scale" strategy has delivered 13% revenue growth with commercial traction further accelerating into FY26.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
Good to see new and familiar faces at CTAD 2025. Great energy, enthusiasm and innovation from the Alzheimer’s research community, bringing new diagnosis, treatment and care approaches to patients.
December 4, 2025 at 2:01 PM
Good to see new and familiar faces at CTAD 2025. Great energy, enthusiasm and innovation from the Alzheimer’s research community, bringing new diagnosis, treatment and care approaches to patients.
Neuromelanin-sensitive (NM) MRI is emerging as a transformative tool in Parkinson's clinical research. In this blog, Richard Joules, Associate Director R&D, explores the evolving role of Neuromelanin imaging in Parkinson's disease clinical trials.
Read more:
🔗 ixico.com/blogs/the-em...
Read more:
🔗 ixico.com/blogs/the-em...
December 3, 2025 at 10:27 AM
Neuromelanin-sensitive (NM) MRI is emerging as a transformative tool in Parkinson's clinical research. In this blog, Richard Joules, Associate Director R&D, explores the evolving role of Neuromelanin imaging in Parkinson's disease clinical trials.
Read more:
🔗 ixico.com/blogs/the-em...
Read more:
🔗 ixico.com/blogs/the-em...
GLP-1 therapies are attracting attention and traction in Alzheimer’s research, but vascular co-pathology remains a critical factor in trial design. In the run-up to #CTAD2025, IXICO CSO Robin Wolz explains why vascular phenotyping matters.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
December 1, 2025 at 10:56 AM
GLP-1 therapies are attracting attention and traction in Alzheimer’s research, but vascular co-pathology remains a critical factor in trial design. In the run-up to #CTAD2025, IXICO CSO Robin Wolz explains why vascular phenotyping matters.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
To coincide with IXICO’s participation in the 18th CTAD conference we are delighted to announce the appointment of two leading global experts in the field of Alzheimer’s Disease (AD) and cerebrovascular disease (CVD) as advisors.
Read more here: ixico.com/news-and-res...
Read more here: ixico.com/news-and-res...
December 1, 2025 at 7:14 AM
To coincide with IXICO’s participation in the 18th CTAD conference we are delighted to announce the appointment of two leading global experts in the field of Alzheimer’s Disease (AD) and cerebrovascular disease (CVD) as advisors.
Read more here: ixico.com/news-and-res...
Read more here: ixico.com/news-and-res...
We’re heading to #CTAD2025 next week in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
November 26, 2025 at 11:18 AM
We’re heading to #CTAD2025 next week in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
Let’s connect at #CTAD2025 (Dec 1–4)
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
November 19, 2025 at 12:23 PM
Let’s connect at #CTAD2025 (Dec 1–4)
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
Today, IXICO announce it has won a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD).
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
November 17, 2025 at 7:08 AM
Today, IXICO announce it has won a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD).
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
November 11, 2025 at 2:10 PM
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
Integrating plasma biomarkers with MRI is reshaping Alzheimer's clinical trials. This dual approach improves enrolment precision, reduces screen failures & boosts efficiency.
Read here:
🔗 ixico.com/news-and-res...
Read here:
🔗 ixico.com/news-and-res...
October 28, 2025 at 4:41 PM
Integrating plasma biomarkers with MRI is reshaping Alzheimer's clinical trials. This dual approach improves enrolment precision, reduces screen failures & boosts efficiency.
Read here:
🔗 ixico.com/news-and-res...
Read here:
🔗 ixico.com/news-and-res...
James Chandler, Chief Business Officer at IXICO, will be at BIO-Europe in Vienna, Austria, on November 3–5!
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
October 23, 2025 at 11:40 AM
James Chandler, Chief Business Officer at IXICO, will be at BIO-Europe in Vienna, Austria, on November 3–5!
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
🧠 Happening Tomorrow!
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
October 21, 2025 at 12:01 PM
🧠 Happening Tomorrow!
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
Congratulations to Roche Diagnostics USA on receiving FDA clearance for the Elecsys® pTau181 blood test. The first blood test approved for use in primary care to help rule out Alzheimer’s related amyloid pathology.
diagnostics.roche.com/us/en/news-l...
diagnostics.roche.com/us/en/news-l...
October 20, 2025 at 12:10 PM
Congratulations to Roche Diagnostics USA on receiving FDA clearance for the Elecsys® pTau181 blood test. The first blood test approved for use in primary care to help rule out Alzheimer’s related amyloid pathology.
diagnostics.roche.com/us/en/news-l...
diagnostics.roche.com/us/en/news-l...
🧠 IXICO Capital Markets Day
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: [email protected]
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: [email protected]
October 17, 2025 at 10:20 AM
🧠 IXICO Capital Markets Day
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: [email protected]
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: [email protected]
Our CEO Bram Goorden talks with VOX Market’s Paul Hill about the company’s strong performance in 2025, highlighting above-guidance revenue delivery and continued progress in its strategic focus areas.
▶️ Watch here: www.voxmarkets.co.uk/articles/q-a...
▶️ Watch here: www.voxmarkets.co.uk/articles/q-a...
Q&A with IXICO CEO Bram Goorden - Vox Markets
In this fascinating interview, CEO Bram Goorden of IXICO - an AI powered medical imaging analytics firm - takes me through today’s positive Sept FY’25 trading update alongside yesterday’s 2 impressive...
www.voxmarkets.co.uk
October 16, 2025 at 12:56 PM
Our CEO Bram Goorden talks with VOX Market’s Paul Hill about the company’s strong performance in 2025, highlighting above-guidance revenue delivery and continued progress in its strategic focus areas.
▶️ Watch here: www.voxmarkets.co.uk/articles/q-a...
▶️ Watch here: www.voxmarkets.co.uk/articles/q-a...
IXICO FY25 trading update now live.
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
October 16, 2025 at 6:33 AM
IXICO FY25 trading update now live.
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
New contract + AD trial extension for IXICO.
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
October 15, 2025 at 6:07 AM
New contract + AD trial extension for IXICO.
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
1 week to go! Discover how imaging is transforming Alzheimer’s disease clinical trials & uncovering new therapeutic paths.
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
October 14, 2025 at 10:53 AM
1 week to go! Discover how imaging is transforming Alzheimer’s disease clinical trials & uncovering new therapeutic paths.
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...